PURE Bioscience, Inc.
PURE
$0.0675
$0.006711.02%
OTC PK
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.34% | 19.94% | -22.99% | -21.26% | 8.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.34% | 19.94% | -22.99% | -21.26% | 8.35% |
| Cost of Revenue | 13.66% | 10.07% | -17.50% | -29.18% | -13.27% |
| Gross Profit | 9.69% | 28.25% | -26.47% | -14.33% | 31.63% |
| SG&A Expenses | -22.24% | -18.22% | -17.89% | -11.98% | 0.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.55% | -13.49% | -17.45% | -15.10% | -1.87% |
| Operating Income | 28.52% | 24.79% | 11.81% | 9.87% | 6.63% |
| Income Before Tax | 32.32% | 20.36% | 6.26% | 26.74% | 2.17% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.32% | 20.36% | 6.26% | 26.74% | 2.17% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.32% | 20.36% | 6.26% | 26.74% | 2.17% |
| EBIT | 28.52% | 24.79% | 11.81% | 9.87% | 6.63% |
| EBITDA | 25.35% | 21.84% | 12.46% | 13.40% | 7.02% |
| EPS Basic | 32.47% | 21.11% | 6.06% | 26.88% | 2.53% |
| Normalized Basic EPS | 33.33% | 19.64% | 7.32% | 2.50% | 2.04% |
| EPS Diluted | 32.47% | 21.11% | 6.06% | 26.88% | 2.53% |
| Normalized Diluted EPS | 33.33% | 19.64% | 7.32% | 2.50% | 2.04% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.28% | 0.45% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.28% | 0.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |